神经保护
药物输送
血脑屏障
医学
药理学
组织纤溶酶原激活剂
脂质体
冲程(发动机)
缺血
药品
缺血性中风
脑缺血
纳米技术
中枢神经系统
材料科学
内科学
工程类
机械工程
作者
Tatsuya Fukuta,Naoto Oku,Kentaro Kogure
出处
期刊:Pharmaceutics
[MDPI AG]
日期:2022-02-04
卷期号:14 (2): 361-361
被引量:12
标识
DOI:10.3390/pharmaceutics14020361
摘要
Ischemic stroke is still one of the leading causes of high mortality and severe disability worldwide. Therapeutic options for ischemic stroke and subsequent cerebral ischemia/reperfusion injury remain limited due to challenges associated with drug permeability through the blood-brain barrier (BBB). Neuroprotectant delivery with nanoparticles, including liposomes, offers a promising solution to address this problem, as BBB disruption following ischemic stroke allows nanoparticles to pass through the intercellular gaps between endothelial cells. To ameliorate ischemic brain damage, a number of nanotherapeutics encapsulating neuroprotective agents, as well as surface-modified nanoparticles with specific ligands targeting the injured brain regions, have been developed. Combination therapy with nanoparticles encapsulating neuroprotectants and tissue plasminogen activator (t-PA), a globally approved thrombolytic agent, has been demonstrated to extend the narrow therapeutic time window of t-PA. In addition, the design of biomimetic drug delivery systems (DDS) employing circulating cells (e.g., leukocytes, platelets) with unique properties has recently been investigated to overcome the injured BBB, utilizing these cells' inherent capability to penetrate the ischemic brain. Herein, we review recent findings on the application and utility of nanoparticle DDS, particularly liposomes, and various approaches to developing biomimetic DDS functionalized with cellular membranes/membrane proteins for the treatment of ischemic stroke.
科研通智能强力驱动
Strongly Powered by AbleSci AI